Effects of an inhibitor of tripeptidyl peptidase II (Ala-Ala-Phe-chloromethylketone) and its combination with an inhibitor of the chymotrypsin-like activity of the proteasome (PSI) on apoptosis, cell cycle and proteasome activity in U937 cells
Bury, M.; Młynarczuk, I.; Pleban, E.; Hoser, G.; Kawiak, J.; Wójcik, C.
Folia Histochemica et Cytobiologica 39(2): 131-132
2001
ISSN/ISBN: 0239-8508
PMID: 11374791
Accession: 010545397
AAF-AMC is not a specific TPP II substrate, since it is also hydrolyzed by purified proteasomes. Moreover, AAF-cmk, claimed to be a specific TPP II inhibitor, also inhibits the chymotrypsin-like activity of the proteasome. While AAF-cmk itself is mildly cytostatic to U-937 cells and induces cell cycle block in G1, its combination with PSI does not induce an increase in the cytostatic/cytotoxic effects.
PDF emailed within 1 workday: $29.90
Related References
Wójcik, C.; Stoklosa, T.; Giermasz, A.; Golab, J.; Zagozdzon, R.; Kawiak, J.; Wilk, S.; Komar, A.; Kaca, A.; Malejczyk, J.; Jakóbisiak, M. 1997: Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome Apoptosis: An International Journal on Programmed Cell Death 2(5): 455-462Lee, M.Jae.; Miller, Z.; Park, J.Eun.; Bhattarai, D.; Lee, W.; Kim, K.Bo. 2019: H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth Scientific Reports 9(1): 4089
Zhang, Q.; Huang, J.; Li, D.-Q.; He, Y.-D. 2012: Effects of proteasome inhibitor MG132 on cell proliferation, apoptosis, and cell cycle in HEC-1B and Ishikawa cells Sichuan da Xue Xue Bao. Yi Xue Ban 43(6): 830
Zubkowicz, M.; Cebula, B.; Linke, A.; Janus, A.; Robak, T.; Smolewski, P. 2006: Cytotoxic activity of rapamycin, the mTOR kinase inhibitor, used alone or in combination with bortezomib, proteasome inhibitor, on multiple myeloma cells in vitro Acta Haematologica Polonica 37(3): 373-386
Wójcik, C. 1997: An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines Folia Histochemica et Cytobiologica 35(4): 211-214
Gu, J.J.; Hernandez-Ilizaliturri, F.J.; Kaufman, G.P.; Czuczman, N.M.; Mavis, C.; Skitzki, J.J.; Czuczman, M.S. 2013: The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma British Journal of Haematology 162(5): 657-669
Bialy, L.P.; Kuckelkorn, U.; Henklein, P.; Fayet, J.; Wilczyński, G.M.; Kamiński, A.; Mlynarczuk-Bialy, I. 2019: Changes in spatio-temporal localization of tripeptidyl peptidase II (TPPII) in murine colon adenocarcinoma cells during aggresome formation: a microscopy study based on a novel fluorescent proteasome inhibitor Histology and Histopathology 34(4): 359-372
Alexandrova, A.; Petrov, L.; Georgieva, A.; Kirkova, M.; Kukan, M. 2008: Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver Cell Biochemistry and Function 26(3): 392-398
Wójcik, C.; Schroeter, D.; Wilk, S.; Lamprecht, J.; Paweletz, N. 1996: Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome European Journal of Cell Biology 71(3): 311-318
Wójcik, C.; Schroeter, D.; Stoehr, M.; Wilk, S.; Paweletz, N. 1996: An inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces arrest in G2-phase and metaphase in HeLa cells European Journal of Cell Biology 70(2): 172-178
David, E.; Sun, S-Yong.; Waller, E.K.; Chen, J.; Khuri, F.R.; Lonial, S. 2005: The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood 106(13): 4322-4329
Soriano, G.P.; Besse, L.; Li, N.; Kraus, M.; Besse, A.; Meeuwenoord, N.; Bader, J.; Everts, B.; den Dulk, H.; Overkleeft, H.S.; Florea, B.I.; Driessen, C. 2016: Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism Leukemia 30(11): 2198-2207
Figueiredo-Pereira, M.E.; Berg, K.A.; Wilk, S. 1994: A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell Journal of Neurochemistry 63(4): 1578-1581
Bei, Z.H.E.N.G.; Georgakis, G.V.; Yang, L.I.; Bharti, A.; Mcconkey, D.; Aggarwal, B.B.; Younes, A. 2004: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors Clinical Cancer Research 10(9): 3207-3215
Jiang, X.-X.; Zhang, Q.-L.; Chen, X.-Y.; Wu, W.-L.; Shen, Z.-X.; Zhao, W.-L. 2009: Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells Zhongguo Shi Yan Xue Ye Xue Za Zhi 17(5): 1215-1219
Biały, L.P.; Ziemba, H.; Pleban, E.; Wójcik, C. 2002: Effects of the combination of a proteasome inhibitor (PSI) and an inhibitor of ubiquitin-ligases (Leu-Ala) on the ultrastructure of human leukemic U937 cells Folia Histochemica et Cytobiologica 40(2): 135-136
Zheng, B.; Georgakis, G.V.; Li, Y.; Bharti, A.; McConkey, D.; Aggarwal, B.B.; Younes, A. 2004: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10(9): 3207-3215
Marcilla, M.; Villasevil, E.M.; de Castro, J.é A.L.óp. 2008: Tripeptidyl peptidase Ii is dispensable for the generation of both proteasome-dependent and proteasome-independent ligands of HLA-B27 and other class i molecules European Journal of Immunology 38(3): 631-639
Tanaka, H.; Katagiri, M.; Arima, S.; Inokoshi, J.; Matsuzaki, K.; Hayashi, M.; Omura, S. 1996: Neuronal Differentiation Of Neuro 2A Cells By The Cell Cycle Inhibitors Lactacystin (Proteasome Inhibitor) And Trichostatin A (Histone Deacetylase Inhibitor) Biochemical Society Transactions 24(4): 554S.2-554S
Eda, H.; Santo, L.; Cirstea, D.D.; Yee, A.J.; Scullen, T.A.; Nemani, N.; Mishima, Y.; Waterman, P.R.; Arastu-Kapur, S.; Evans, E.; Singh, J.; Kirk, C.J.; Westlin, W.F.; Raje, N.S. 2014: A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity Leukemia 28(9): 1892-1901